Karim F. Damji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karim F. Damji has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Rama Behki
3 shared publications- Andrew Crichton
Univ Calgary, Sect Ophthalmol, Calgary, AB, Canada
2 shared publications W G Hodge
2 shared publicationsA Arnarsson
Department of Ophthalmology, University of Iceland, Reykjavik, Iceland
1 shared publicationA G P Konstas
1 shared publicationA M Bovell
1 shared publication
Latest Publications
- 1 February 2007
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 42 (1) , 66-74
Canadian perspectives in glaucoma management: The role of central corneal thickness
- 1 February 2007
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 42 (1) , 66-74
Canadian perspectives in glaucoma management: The role of central corneal thickness
- 1 January 2007
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 42 (1) , 66-74
Canadian perspectives in glaucoma management: the role of central corneal thickness
- 1 January 2007
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 42 (1) , 66-74
Canadian perspectives in glaucoma management: the role of central corneal thickness
- 17 August 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (12) , 1490-1494
Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial
Aims: To compare selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT), in terms of intraocular pressure (IOP) lowering, in patients with open-angle glaucoma. Methods: 176 eyes of 152 patients were enrolled in this study, 89 in the SLT and 87 in the ALT groups. Patients were randomised to receive either SLT or ALT treatment to 180° of the trabecular meshwork. Patients were followed up to 12 months after treatment. The main outcome measured was IOP lowering at 12 months after treatment, compared between the SLT and ALT groups. Results: No significant difference (p = 0.846) was found in mean decrease in IOP between the SLT (5.86 mm Hg) and ALT (6.04 mm Hg) groups at 1 year or at any other time points, nor were there any significant differences in the rate of early or late complications between the two groups. Conclusions: SLT is equivalent to ALT in terms of IOP lowering at 1 year, and is a safe and effective procedure for patients with open-angle glaucoma.
- 17 August 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (12) , 1490-1494
Selective laser trabeculoplasty versus argon laser trabeculoplasty: results from a 1-year randomised clinical trial
Aims: To compare selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT), in terms of intraocular pressure (IOP) lowering, in patients with open-angle glaucoma. Methods: 176 eyes of 152 patients were enrolled in this study, 89 in the SLT and 87 in the ALT groups. Patients were randomised to receive either SLT or ALT treatment to 180° of the trabecular meshwork. Patients were followed up to 12 months after treatment. The main outcome measured was IOP lowering at 12 months after treatment, compared between the SLT and ALT groups. Results: No significant difference (p = 0.846) was found in mean decrease in IOP between the SLT (5.86 mm Hg) and ALT (6.04 mm Hg) groups at 1 year or at any other time points, nor were there any significant differences in the rate of early or late complications between the two groups. Conclusions: SLT is equivalent to ALT in terms of IOP lowering at 1 year, and is a safe and effective procedure for patients with open-angle glaucoma.
- 13 April 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (8) , 1014-1018
Intraocular pressure following phacoemulsification in patients with and without exfoliation syndrome: a 2 year prospective study
To determine the long term intraocular pressure (IOP) response to phacoemulsification in patients with and without exfoliation syndrome (XFS). Prospective, multicentre, cohort study with the following inclusion criteria: age over 50 years, open iridocorneal angle, and cataract. Two groups were enrolled: those with XFS and those without. The main outcome was mean IOP reduction 2 years after phacoemulsification cataract extraction (PCE). Univariate and multivariate analyses were performed. 183 patients were enrolled, 71 with and 112 without XFS. There were 29 patients with glaucoma in both groups. Mean baseline IOP was higher in XFS compared to control eyes (17.60 (SD 3.23) mm Hg v 16.08 (3.18) mm Hg, p = 0.002). Overall IOP reduction was significantly greater in the XFS group at the 2 year time point (-1.85 mm Hg v -0.62 mm Hg in the controls (p = 0.0037)). Multivariate analysis demonstrated that the IOP lowering effect in the XFS group may be related to irrigation volume at the time of surgery. In the subgroup analyses IOP lowering was significantly greater in the XFS and XFG patients than in controls without glaucoma, and POAG controls, respectively. The percentage of patients with a postoperative IOP spike was similar and relatively high in both XFS and control groups (34% v 25%; p = 0.54). IOP decreases more in patients with XFS following PCE compared to control eyes without XFS. This effect is more pronounced in glaucoma patients and persists for at least 2 years.
- 13 April 2006
- Published by BMJ in British Journal of Ophthalmology
- Vol. 90 (8) , 1014-1018
Intraocular pressure following phacoemulsification in patients with and without exfoliation syndrome: a 2 year prospective study
To determine the long term intraocular pressure (IOP) response to phacoemulsification in patients with and without exfoliation syndrome (XFS). Prospective, multicentre, cohort study with the following inclusion criteria: age over 50 years, open iridocorneal angle, and cataract. Two groups were enrolled: those with XFS and those without. The main outcome was mean IOP reduction 2 years after phacoemulsification cataract extraction (PCE). Univariate and multivariate analyses were performed. 183 patients were enrolled, 71 with and 112 without XFS. There were 29 patients with glaucoma in both groups. Mean baseline IOP was higher in XFS compared to control eyes (17.60 (SD 3.23) mm Hg v 16.08 (3.18) mm Hg, p = 0.002). Overall IOP reduction was significantly greater in the XFS group at the 2 year time point (-1.85 mm Hg v -0.62 mm Hg in the controls (p = 0.0037)). Multivariate analysis demonstrated that the IOP lowering effect in the XFS group may be related to irrigation volume at the time of surgery. In the subgroup analyses IOP lowering was significantly greater in the XFS and XFG patients than in controls without glaucoma, and POAG controls, respectively. The percentage of patients with a postoperative IOP spike was similar and relatively high in both XFS and control groups (34% v 25%; p = 0.54). IOP decreases more in patients with XFS following PCE compared to control eyes without XFS. This effect is more pronounced in glaucoma patients and persists for at least 2 years.
- 1 September 2005
- Vol. 51 (9) , 1229-37
Chronic open-angle glaucoma. Review for primary care physicians.
Chronic open-angle glaucoma (COAG) is a leading cause of irreversible blindness worldwide, including in Canada. It presents a challenge in diagnosis, as disease often progresses without symptoms; an estimated 50% of cases are undetected. MEDLINE searches, reference lists of articles, and expert knowledge from one of the authors (K.F.D.), a glaucoma specialist, were used. A casefinding approach using early referral to optometrists and ophthalmologists for early detection of COAG is helpful for patients with risk factors such as age above 50, a positive family history, black race, and myopia. Moderate evidence for referral also exists for the following risk factors: hypertension, type 2 diabetes mellitus, hypothyroidism, and sleep apnea. Treatment with intraocular pressure-lowering medication can arrest or slow the course of the disease, permitting patients to retain good visual function. Family physicians should be aware that some intraocular pressure-lowering medications, particularly topical beta-blockers, can pose iatrogenic harm to patients and result in or exacerbate such conditions as asthma, cardiovascular disturbances, depression, and sexual dysfunction. Appropriate referral patterns and an understanding of common as well as serious side effects of glaucoma medications are important in optimizing management of patients at risk of developing, or who have, COAG.
- 1 September 2005
- Vol. 51 (9) , 1229-37
Chronic open-angle glaucoma. Review for primary care physicians.
Chronic open-angle glaucoma (COAG) is a leading cause of irreversible blindness worldwide, including in Canada. It presents a challenge in diagnosis, as disease often progresses without symptoms; an estimated 50% of cases are undetected. MEDLINE searches, reference lists of articles, and expert knowledge from one of the authors (K.F.D.), a glaucoma specialist, were used. A casefinding approach using early referral to optometrists and ophthalmologists for early detection of COAG is helpful for patients with risk factors such as age above 50, a positive family history, black race, and myopia. Moderate evidence for referral also exists for the following risk factors: hypertension, type 2 diabetes mellitus, hypothyroidism, and sleep apnea. Treatment with intraocular pressure-lowering medication can arrest or slow the course of the disease, permitting patients to retain good visual function. Family physicians should be aware that some intraocular pressure-lowering medications, particularly topical beta-blockers, can pose iatrogenic harm to patients and result in or exacerbate such conditions as asthma, cardiovascular disturbances, depression, and sexual dysfunction. Appropriate referral patterns and an understanding of common as well as serious side effects of glaucoma medications are important in optimizing management of patients at risk of developing, or who have, COAG.
- Open Access
- 1 January 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (1) , 36-39
Epidemiology of the optic nerve grey crescent in the Reykjavik Eye Study
Aim: To establish the epidemiology of the grey crescent in a white population within the age range most susceptible to glaucoma. Methods: Bruce Shields was first to use this term to describe a localised, physiological pigmentation of the optic nerve neuroretinal rim tissue that is distinct from peripapillary pigmentation. An experienced glaucomatologist (KFD) evaluated stereofundus photographs of the participants of the Reykjavik Eye Study (RES)—a random sample from the national population census including people 50 years and older. 1012 right eyes could be evaluated for grey crescent. Results: The prevalence of grey crescent in the right eyes was 22.0% (95% CI 10 to 25). It was more commonly found in women (27.0%: 95% CI 23 to 30) than in men (17.0%: 95% CI 14 to 21), and was most often located temporally (36.9%), 360° (15.9%), or nasally (15.4%). The spherical equivalent was +1.30 dioptres (D) for those with and +0.80 D for those without grey crescent (p = 0.002), respectively. Vertical optic disc diameters were 0.203 v 0.195 units (pConclusions: The grey crescent needs to be recognised as a physiological variant in order to avoid falsely labelling eyes as having glaucomatous optic nerve damage.
- 1 January 2005
- Published by BMJ in British Journal of Ophthalmology
- Vol. 89 (1) , 36-39
Open AccessEpidemiology of the optic nerve grey crescent in the Reykjavik Eye Study
Aim: To establish the epidemiology of the grey crescent in a white population within the age range most susceptible to glaucoma. Methods: Bruce Shields was first to use this term to describe a localised, physiological pigmentation of the optic nerve neuroretinal rim tissue that is distinct from peripapillary pigmentation. An experienced glaucomatologist (KFD) evaluated stereofundus photographs of the participants of the Reykjavik Eye Study (RES)—a random sample from the national population census including people 50 years and older. 1012 right eyes could be evaluated for grey crescent. Results: The prevalence of grey crescent in the right eyes was 22.0% (95% CI 10 to 25). It was more commonly found in women (27.0%: 95% CI 23 to 30) than in men (17.0%: 95% CI 14 to 21), and was most often located temporally (36.9%), 360° (15.9%), or nasally (15.4%). The spherical equivalent was +1.30 dioptres (D) for those with and +0.80 D for those without grey crescent (p = 0.002), respectively. Vertical optic disc diameters were 0.203 v 0.195 units (pConclusions: The grey crescent needs to be recognised as a physiological variant in order to avoid falsely labelling eyes as having glaucomatous optic nerve damage.
- 1 April 2003
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 38 (3) , 189-197
Canadian perspectives in glaucoma management: setting target intraocular pressure range
- 1 April 2003
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 38 (3) , 189-197
Canadian perspectives in glaucoma management: setting target intraocular pressure range
- 1 October 1997
- Published by Elsevier in Ophthalmology
- Vol. 104 (10) , 1525-1526
Reduction of IOP after PRK
- 1 October 1997
- Published by Elsevier in Ophthalmology
- Vol. 104 (10) , 1525-1526
Reduction of IOP after PRK